Tyr Pharma stock rated Hold after mixed trial results for efzofitimod; promising secondary data, but there remains uncertainty. Find out why ATYR is a Hold.

Dr. Kurt Miceli, medical director for the advocacy group Do No Harm, presented at the CDC’s twice-yearly conference to update U.S. medical codes to include side effects for detransitioners, or those ...

Stock markets are in trouble if soft U.S. economic data along with signs of weakness abroad put worries about global ...

The Biden Administration insisted on calling the January 6 riot an armed insurrection for years, and targeted parents who ...

As we continue to observe National Recovery Month, Homeland Security Today contributor Robert Patterson – former Acting ...

A federal judge ordered the agency to give detainees at 26 Federal Plaza adequate space, hygiene supplies and the chance to ...

Audrey was in seventh grade when her bones started breaking: eight in total, over six months. Some of them broke dramatically ...

A drug called riluzole, commonly used to treat amyotrophic lateral sclerosis (ALS) and other motor neuron diseases, could also assist in recovery from ...

Data can expose injustice, but it can also be turned into a tool of control. How do we know when data collection is helpful ...

Forget the glorious successes of past breakthroughs—the real justification for research investment is what we get for our ...

A large-scale international study led by the University of Liverpool and funded by the Epilepsy Research Institute UK has ...

What doesn't make sense is this sudden urgency among an unknown "business community" cabal. This secret society is pulling levers of power with zero accountability, says columnist Ginnie Graham.